Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety of Paxlovid (Nirmatrelvir/Ritonavir) in Hemodialysis Patients With SARS-CoV-2 Infection

NCT05366192 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05366192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety of Paxlovid (Nirmatrelvir/Ritonavir) in Hemodialysis Patients With SARS-CoV-2 Infection
Lead sponsor
RenJi Hospital
Phase
Phase 4
Overall status
Completed
Start date
May 6, 2022
Completion date
June 8, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety issues